Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia

Pilar de la Puente, Ellen Weisberg, Barbara Muz, Atsushi Nonami, Micah Luderer, Richard M. Stone, Junia V. Melo, James D. Griffin, Abdel Kareem Azab

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Current treatment options as well as clinical efficacy are limited for chronic myelogenous leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). In response to the pressing need for more efficacious treatment approaches and strategies to override drug resistance in advanced stage CML, Ph+ ALL, and AML, we investigated the effects of inhibition of ILK as a potentially novel and effective approach to treatment of these challenging malignancies. Using the small molecule ILK inhibitor, Cpd22, and ILK knockdown, we investigated the importance of ILK in the growth and viability of leukemia. Our results suggest that the ILK inhibition may be an effective treatment for CML, Ph+ ALL, and AML as a single therapy, with ILK expression levels positively correlating with the efficacy of ILK inhibition. The identification of ILK as a novel target for leukemia therapy warrants further investigation as a therapeutic approach that could be of potential clinical benefit in both acute and chronic myeloid leukemias.

Original languageEnglish
Pages (from-to)1299-1308
Number of pages10
JournalLeukemia Research
Volume39
Issue number11
DOIs
Publication statusPublished - Apr 24 2015
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute Myeloid Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
Therapeutics
Drug Resistance
Growth
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

de la Puente, P., Weisberg, E., Muz, B., Nonami, A., Luderer, M., Stone, R. M., ... Azab, A. K. (2015). Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. Leukemia Research, 39(11), 1299-1308. https://doi.org/10.1016/j.leukres.2015.09.005

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. / de la Puente, Pilar; Weisberg, Ellen; Muz, Barbara; Nonami, Atsushi; Luderer, Micah; Stone, Richard M.; Melo, Junia V.; Griffin, James D.; Azab, Abdel Kareem.

In: Leukemia Research, Vol. 39, No. 11, 24.04.2015, p. 1299-1308.

Research output: Contribution to journalArticle

de la Puente, P, Weisberg, E, Muz, B, Nonami, A, Luderer, M, Stone, RM, Melo, JV, Griffin, JD & Azab, AK 2015, 'Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia', Leukemia Research, vol. 39, no. 11, pp. 1299-1308. https://doi.org/10.1016/j.leukres.2015.09.005
de la Puente, Pilar ; Weisberg, Ellen ; Muz, Barbara ; Nonami, Atsushi ; Luderer, Micah ; Stone, Richard M. ; Melo, Junia V. ; Griffin, James D. ; Azab, Abdel Kareem. / Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. In: Leukemia Research. 2015 ; Vol. 39, No. 11. pp. 1299-1308.
@article{b8fe49f3c8d34526a4d7130c6c363ade,
title = "Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia",
abstract = "Current treatment options as well as clinical efficacy are limited for chronic myelogenous leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). In response to the pressing need for more efficacious treatment approaches and strategies to override drug resistance in advanced stage CML, Ph+ ALL, and AML, we investigated the effects of inhibition of ILK as a potentially novel and effective approach to treatment of these challenging malignancies. Using the small molecule ILK inhibitor, Cpd22, and ILK knockdown, we investigated the importance of ILK in the growth and viability of leukemia. Our results suggest that the ILK inhibition may be an effective treatment for CML, Ph+ ALL, and AML as a single therapy, with ILK expression levels positively correlating with the efficacy of ILK inhibition. The identification of ILK as a novel target for leukemia therapy warrants further investigation as a therapeutic approach that could be of potential clinical benefit in both acute and chronic myeloid leukemias.",
author = "{de la Puente}, Pilar and Ellen Weisberg and Barbara Muz and Atsushi Nonami and Micah Luderer and Stone, {Richard M.} and Melo, {Junia V.} and Griffin, {James D.} and Azab, {Abdel Kareem}",
year = "2015",
month = "4",
day = "24",
doi = "10.1016/j.leukres.2015.09.005",
language = "English",
volume = "39",
pages = "1299--1308",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia

AU - de la Puente, Pilar

AU - Weisberg, Ellen

AU - Muz, Barbara

AU - Nonami, Atsushi

AU - Luderer, Micah

AU - Stone, Richard M.

AU - Melo, Junia V.

AU - Griffin, James D.

AU - Azab, Abdel Kareem

PY - 2015/4/24

Y1 - 2015/4/24

N2 - Current treatment options as well as clinical efficacy are limited for chronic myelogenous leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). In response to the pressing need for more efficacious treatment approaches and strategies to override drug resistance in advanced stage CML, Ph+ ALL, and AML, we investigated the effects of inhibition of ILK as a potentially novel and effective approach to treatment of these challenging malignancies. Using the small molecule ILK inhibitor, Cpd22, and ILK knockdown, we investigated the importance of ILK in the growth and viability of leukemia. Our results suggest that the ILK inhibition may be an effective treatment for CML, Ph+ ALL, and AML as a single therapy, with ILK expression levels positively correlating with the efficacy of ILK inhibition. The identification of ILK as a novel target for leukemia therapy warrants further investigation as a therapeutic approach that could be of potential clinical benefit in both acute and chronic myeloid leukemias.

AB - Current treatment options as well as clinical efficacy are limited for chronic myelogenous leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). In response to the pressing need for more efficacious treatment approaches and strategies to override drug resistance in advanced stage CML, Ph+ ALL, and AML, we investigated the effects of inhibition of ILK as a potentially novel and effective approach to treatment of these challenging malignancies. Using the small molecule ILK inhibitor, Cpd22, and ILK knockdown, we investigated the importance of ILK in the growth and viability of leukemia. Our results suggest that the ILK inhibition may be an effective treatment for CML, Ph+ ALL, and AML as a single therapy, with ILK expression levels positively correlating with the efficacy of ILK inhibition. The identification of ILK as a novel target for leukemia therapy warrants further investigation as a therapeutic approach that could be of potential clinical benefit in both acute and chronic myeloid leukemias.

UR - http://www.scopus.com/inward/record.url?scp=84955719448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955719448&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2015.09.005

DO - 10.1016/j.leukres.2015.09.005

M3 - Article

VL - 39

SP - 1299

EP - 1308

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 11

ER -